Mizuho Upgrades Belite Bio to Outperform, Raises Price Target to $194

Benzinga · 3d ago
Mizuho analyst Graig Suvannavejh upgrades Belite Bio (NASDAQ:BLTE) from Neutral to Outperform and raises the price target from $105 to $194.